GLP-1 Prior Authorization Guide 2026: How to Get Your Medication Approved

If your doctor writes you a prescription for Wegovy or Zepbound, there’s roughly a 50/50 chance your insurance company will require prior authorization before they’ll cover it. This isn’t a denial—it’s a request for documentation proving the medication is medically necessary. The process is frustrating, but it’s navigable if you know what to expect.

According to 2025 data from the Kaiser Family Foundation, approximately 46% of large employers that cover GLP-1 medications require prior authorization. For individual and marketplace plans, the rate is even higher. Understanding the process before you start can save you weeks of delays.

What Is Prior Authorization?

Prior authorization (sometimes called “prior auth” or “PA”) is a requirement from your health insurance company that your doctor get approval before prescribing certain medications. The insurer wants to verify that the medication is medically necessary, that you’ve tried other treatments first (called “step therapy”), and that you meet specific clinical criteria.

For GLP-1 medications, prior authorization criteria typically include a minimum BMI threshold (usually 30 or higher, or 27 with a weight-related comorbidity), documentation of prior weight management attempts such as diet and exercise programs, and sometimes evidence that you’ve tried older, cheaper medications first.

The Standard Prior Authorization Criteria for GLP-1s

While every insurer has slightly different requirements, most prior authorization forms for GLP-1 weight management medications ask for similar documentation. Your provider will need to submit clinical evidence that includes your current BMI or body weight, relevant comorbidities like type 2 diabetes, hypertension, sleep apnea, or cardiovascular disease, documentation of lifestyle modification attempts lasting at least three to six months, and lab work including fasting glucose or HbA1c levels.

Step-by-Step: How to Navigate the Process

Step 1: Verify Your Coverage Before the Appointment

Before your doctor even writes the prescription, call the number on the back of your insurance card and ask specifically: “Does my plan cover Wegovy (or Zepbound) for weight management? Is prior authorization required? What are the clinical criteria?” Get the answers in writing if possible. Some insurers have online portals where you can check formulary coverage directly.

Step 2: Prepare Your Documentation

The most common reason for prior auth denial is incomplete documentation. Before your appointment, gather records showing your weight history over the past 12 months, any documented diet or exercise programs you’ve attempted, your comorbidity diagnoses with supporting lab work, and records from any previous weight management treatments or counseling.

Step 3: Work With Your Provider on the Submission

Your doctor’s office handles the actual submission, but you can help by making sure they have complete information. Many telehealth providers now have dedicated prior auth teams that handle this process routinely. Ask your provider how many prior auth requests they submit per month for GLP-1s and what their approval rate is—experienced providers tend to have higher success rates.

Step 4: Follow Up Relentlessly

Don’t assume no news is good news. Call your insurer every three to five business days to check the status. Document every call: the date, the representative’s name, and what they told you. If the process stalls, ask to speak with a supervisor or the clinical review team directly.

What to Do If You’re Denied

A denial is not the end of the road. According to industry data, approximately 40–60% of first-level appeals for GLP-1 medications are ultimately approved. The appeals process typically involves three levels.

The first-level internal appeal goes back to your insurer with additional clinical documentation from your provider. This is where a detailed letter of medical necessity makes the biggest difference. Your doctor should explain why this specific medication is clinically necessary for you, what alternatives have been tried and failed, and what the expected clinical outcomes are.

If the first appeal fails, most states allow a second-level internal appeal. At this stage, a different reviewer examines the case. Finally, every state has an external review process where an independent third-party physician reviews the decision. External reviews are binding on the insurer in most states, and approval rates at this stage tend to be higher because the reviewer is independent.

The Cardiovascular Indication Workaround

Wegovy received FDA approval for cardiovascular risk reduction in March 2024, based on the landmark SELECT trial showing a 20% reduction in major cardiovascular events. This matters for prior authorization because many insurers that don’t cover GLP-1s for weight management do cover them for cardiovascular risk reduction. If you have established cardiovascular disease or multiple risk factors, your doctor can submit the prior authorization under the cardiovascular indication instead, which may have different (and sometimes easier) approval criteria.

Medicare GLP-1 Coverage in 2026

Medicare coverage for GLP-1 weight management medications expanded significantly in 2026. Under the Trump Administration’s GENEROUS model, Medicare beneficiaries can now access Wegovy and oral Wegovy at approximately $50 per month out-of-pocket. However, this coverage still requires prior authorization, and the clinical criteria are specific to Medicare’s guidelines.

For Medicare patients, the most reliable pathway to coverage remains the type 2 diabetes indication (Ozempic) or the cardiovascular risk reduction indication (Wegovy). The weight management indication is now covered through the GENEROUS model, but the prior auth criteria require documented BMI of 30 or greater and at least one weight-related comorbidity.

When Prior Auth Isn’t Worth the Wait

Sometimes the prior authorization process takes weeks, and you want to start treatment now. In these cases, you have alternatives. The Wegovy pill launched in January 2026 at $149 per month for the starting dose through NovoCare. LillyDirect offers Zepbound vials at $299–$449 per month for cash-pay patients. And manufacturer savings cards can bring commercially insured copays down to as low as $25 per month while you wait for prior auth approval.

The key is to start the prior auth process and explore cash-pay options simultaneously. If your insurance eventually approves coverage, you can transition to insurance-covered medication. If they don’t, you already have a treatment plan in place.